Pfizer (NYSE:PFE) Cut to “Sell” at ValuEngine

ValuEngine downgraded shares of Pfizer (NYSE:PFE) from a hold rating to a sell rating in a research report report published on Saturday, ValuEngine reports.

Other analysts have also recently issued reports about the stock. JPMorgan Chase & Co. set a $46.00 target price on shares of Pfizer and gave the stock a neutral rating in a report on Monday, July 29th. Goldman Sachs Group reaffirmed a buy rating and issued a $49.00 price objective on shares of Pfizer in a report on Monday, June 17th. Morgan Stanley dropped their price objective on shares of Pfizer from $40.00 to $38.00 and set an equal weight rating on the stock in a report on Tuesday, August 27th. Bank of America cut shares of Pfizer from a buy rating to a neutral rating in a report on Tuesday, July 30th. Finally, UBS Group reaffirmed a neutral rating and issued a $43.00 price objective on shares of Pfizer in a report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $45.88.

Shares of NYSE:PFE opened at $36.50 on Friday. The stock has a market capitalization of $204.15 billion, a price-to-earnings ratio of 12.17, a price-to-earnings-growth ratio of 2.94 and a beta of 0.66. Pfizer has a 1-year low of $33.97 and a 1-year high of $46.47. The company’s fifty day moving average is $36.20 and its two-hundred day moving average is $40.66. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47.



Pfizer (NYSE:PFE) last issued its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.05. The company had revenue of $13.26 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm’s revenue was down 1.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.77 earnings per share. Sell-side analysts expect that Pfizer will post 2.81 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd were issued a $0.36 dividend. The ex-dividend date of this dividend was Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.95%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

In other Pfizer news, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the transaction, the executive vice president now owns 489,647 shares of the company’s stock, valued at approximately $21,588,536.23. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the transaction, the insider now directly owns 80,094 shares in the company, valued at approximately $3,524,136. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in PFE. Nuveen Asset Management LLC increased its stake in Pfizer by 2,240.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock valued at $1,563,256,000 after buying an additional 34,544,423 shares during the period. Natixis acquired a new position in Pfizer during the 2nd quarter valued at about $258,466,000. Invesco Ltd. increased its stake in Pfizer by 14.6% during the 2nd quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock valued at $914,857,000 after buying an additional 2,693,349 shares during the period. Thoroughbred Financial Services LLC increased its stake in Pfizer by 4,297.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock valued at $265,668,000 after buying an additional 2,596,269 shares during the period. Finally, Marshall Wace North America L.P. increased its stake in Pfizer by 52.9% during the 1st quarter. Marshall Wace North America L.P. now owns 7,431,974 shares of the biopharmaceutical company’s stock valued at $315,635,000 after buying an additional 2,571,626 shares during the period. 71.68% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: Are FAANG stocks a good investment?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.